eb513503b5
- Source: inbox/queue/2025-xx-neda-anad-glp1-eating-disorders-clinical-guidance.md - Domain: health - Claims: 2, Entities: 2 - Enrichments: 3 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
30 lines
No EOL
1.3 KiB
Markdown
30 lines
No EOL
1.3 KiB
Markdown
---
|
|
title: National Eating Disorders Association (NEDA)
|
|
type: entity
|
|
entity_type: organization
|
|
domain: health
|
|
status: active
|
|
---
|
|
|
|
# National Eating Disorders Association (NEDA)
|
|
|
|
Leading U.S. advocacy and clinical guidance organization for eating disorder treatment and prevention.
|
|
|
|
## Timeline
|
|
|
|
- **2025-01-01** — Published joint clinical guidance with ANAD on GLP-1 receptor agonist use in eating disorder populations, recommending tri-specialist care teams and identifying contraindications including current/past anorexia nervosa, active restrictive behaviors, and severe body image issues
|
|
|
|
## Overview
|
|
|
|
NEDA provides clinical guidance, advocacy, and resources for eating disorder treatment. Their recommendations carry professional authority but no regulatory force—guidance creates clinical standards without legal mandates.
|
|
|
|
## Key Positions
|
|
|
|
**GLP-1 Contraindications (2025):**
|
|
- Current or past anorexia nervosa or atypical anorexia nervosa
|
|
- Active restrictive behaviors, bingeing, or purging
|
|
- Severe body image issues or unstable recovery
|
|
- Lack of appropriate monitoring or multidisciplinary support
|
|
- Signs the medication is being sought solely for weight loss
|
|
|
|
NEDA notes there are no FDA warnings for eating disorder populations—all guidance is professional society recommendation only. |